MedTrace Logo

Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults

NCT06077292 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-04-13

No results posted yet for this study

Summary

The goal of this interventional study is to determine the impact of high potency THC product use on cognitive function of young adults aged 21-25.

The main question it aims to answer is: will cannabis users who switch to less potent THC products demonstrate improved cognitive function compared to baseline?

Other questions this study aims to answer include:

* Can researchers accurately assess THC consumption among frequent cannabis users?
* Can researchers effectively incentivize cannabis users to use less potent THC products?
* Do genetic variations in THC metabolism impact urinary THC excretion?
* Do genetic variations in THC metabolism impact cognitive performance in cannabis users?
* Are quantitative urinary THC values predictive of cognitive impairment?
* How can researchers use research findings to inform harm reduction practices for people who use cannabis?

Participants will submit blood and urine samples and be incentivized to use less potent THC products.

Conditions

Interventions

BEHAVIORAL

15% THC Potency Reduction

Participants will be incentivized to use THC products that are at least 15% less potent than baseline

BEHAVIORAL

35% THC Potency Reduction

Participants will be incentivized to use THC products that are at least 35% less potent than baseline

Sponsors & Collaborators

Principal Investigators

  • Veronika Mesheriakova, MD · University of California, San Francisco

  • Michael Sofis, PhD · Cannabis Public Policy Consulting

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-17
Primary Completion
2026-03-14
Completion
2026-12-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06077292 on ClinicalTrials.gov